Richard Gonzalez - AbbVie Chairman, CEO and Chairman of Executive Committee
| ABBV Stock | USD 166.41 1.75 1.06% |
Chairman
Mr. Richard A. Gonzalez is the Chairman of the Board, Chief Executive Officer of the Company. Mr. Gonzalez is the chairman and chief executive officer of AbbVie. He served as Abbott executive vice president of the pharmaceutical products group from July 2010 to December 2012, and was responsible for Abbott worldwide pharmaceutical business, including commercial operations, research and development, and manufacturing. He also served as president, Abbott Ventures Inc., Abbott medical technology investment arm, from 2009 to 2011. Mr. Gonzalez joined Abbott in 1977 and held various management positions before briefly retiring in 2007, including Abbott president and chief operating officer president, chief operating officer of Abbott Medical Products Group senior vice president and president of Abbott former Hospital Products Division vice president and president of Abbott Health Systems Division and divisional vice president and general manager for Abbott Diagnostics Operations in the United States and Canada. As a result of his service as Abbott executive vice president, Pharmaceutical Products Group, his previous service as Abbott president and chief operating officer and his more than 30year career at Abbott, Mr. Gonzalez has developed valuable business, management and leadership experience, as well as extensive knowledge of AbbVie and its global operations. Mr. Gonzalez experience and knowledge enable him to contribute to AbbVie board key insights into strategic, management, and operational matters. since 2013.
| Age | 70 |
| Tenure | 11 years |
| Address | 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 |
| Phone | 847 932 7900 |
| Web | https://www.abbvie.com |
AbbVie Management Efficiency
The company has return on total asset (ROA) of 0.0807 % which means that it generated a profit of $0.0807 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.352 %, meaning that it created $0.352 on every $100 dollars invested by stockholders. AbbVie's management efficiency ratios could be used to measure how well AbbVie manages its routine affairs as well as how well it operates its assets and liabilities. At this time, AbbVie's Return On Capital Employed is fairly stable compared to the past year. Return On Equity is likely to climb to 0.65 in 2024, whereas Return On Tangible Assets are likely to drop 0.1 in 2024. At this time, AbbVie's Other Assets are fairly stable compared to the past year. Non Currrent Assets Other is likely to climb to about 6.9 B in 2024, whereas Non Current Assets Total are likely to drop slightly above 57.7 B in 2024.Similar Executives
| Showing other executives | CHAIRMAN Age | ||
| Kenneth Frazier | Merck Company | 67 | |
| John Martin | Gilead Sciences | 65 | |
| John Lechleiter | Eli Lilly and | 61 | |
| Lamberto Andreotti | Bristol Myers Squibb | 64 | |
| Ashley McEvoy | Johnson Johnson | 50 | |
| Thibaut Mongon | Johnson Johnson | 51 | |
| Joaquin Duato | Johnson Johnson | 61 | |
| Robert JD | Merck Company | 57 | |
| Giovanni Caforio | Bristol Myers Squibb | 56 | |
| Daniel ODay | Gilead Sciences | 60 | |
| Albert DVM | Pfizer Inc | 62 | |
| Alex Gorsky | Johnson Johnson | 64 | |
| Sandra Peterson | Johnson Johnson | 58 | |
| Jennifer Taubert | Johnson Johnson | 60 | |
| Jorge Mesquita | Johnson Johnson | 56 | |
| Ian Read | Pfizer Inc | 64 | |
| Paulus Stoffels | Johnson Johnson | 57 | |
| Robert Bradway | Amgen Inc | 61 | |
Management Performance
| Return On Equity | 0.35 | ||||
| Return On Asset | 0.0807 |
AbbVie Inc Leadership Team
Elected by the shareholders, the AbbVie's board of directors comprises two types of representatives: AbbVie inside directors who are chosen from within the company, and outside directors, selected externally and held independent of AbbVie. The board's role is to monitor AbbVie's management team and ensure that shareholders' interests are well served. AbbVie's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, AbbVie's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Azita Gerhardt, Executive Vice President - Operations | ||
| Carlos Alban, Vice Chairman, Chief Commercial Officer | ||
| Robert Michael, Vice Chairman, Finance and Commercial Operations and Chief Financial Officer | ||
| Jeffrey Stewart, Executive Vice President, Chief Commercial Officer | ||
| Carrie Strom, Senior Vice President AbbVie and President Global Allergan Aesthetics | ||
| Brett Hart, Independent Director | ||
| William Chase, Executive Vice President - Finance and Administration | ||
| Roxanne Austin, Independent Director | ||
| Perry Siatis, General VP | ||
| Azita SalekiGerhardt, Executive Vice President - Operations | ||
| Scott Reents, Executive CFO | ||
| Thomas Freyman, Independent Director | ||
| Thomas MD, Senior Research | ||
| Edward Rapp, Independent Director | ||
| Richard Gonzalez, Chairman, CEO and Chairman of Executive Committee | ||
| Tracie Haas, Brand Responsibility | ||
| Sanjay Narayan, Chief SVP | ||
| Brian Durkin, Vice President Controller | ||
| Thomas Hurwich, Vice President Controller | ||
| Frederick Waddell, Independent Director | ||
| Robert Alpern, Independent Director | ||
| Thomas Hudson, Senior Vice President Research & Development and Chief Scientific Officer | ||
| Glenn Tilton, Lead Independent Director | ||
| Assil Omar, VP Officer | ||
| Greg Miley, Senior Affairs | ||
| Henry Gosebruch, Executive Vice President Chief Strategy Officer | ||
| Elizabeth Shea, Senior Relations | ||
| Rebecca Roberts, Independent Director | ||
| Edward Liddy, Independent Director | ||
| William Burnside, Independent Director | ||
| Elaine Sorg, Senior Vice President U.S. Commercial Operations | ||
| WulffErik Borcke, Senior Oncology | ||
| Timothy Richmond, Chief Human Resource Officer, Executive Vice President | ||
| Nicholas Donoghoe, Senior Vice President - Enterprise Innovation | ||
| Laura Schumacher, Executive VP of Bus. Devel. and External Affairs, General Counsel and Corporate Secretary | ||
| Roy Roberts, Independent Director | ||
| Michael Severino, Executive Vice President - Research & Development, Chief Scientific Officer | ||
| Melody Meyer, Independent Director |
AbbVie Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is AbbVie a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.35 | ||||
| Return On Asset | 0.0807 | ||||
| Profit Margin | 0.09 % | ||||
| Operating Margin | 0.32 % | ||||
| Current Valuation | 338.67 B | ||||
| Shares Outstanding | 1.77 B | ||||
| Shares Owned By Insiders | 0.10 % | ||||
| Shares Owned By Institutions | 71.94 % | ||||
| Number Of Shares Shorted | 13.12 M | ||||
| Price To Earning | 21.28 X |
Pair Trading with AbbVie
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if AbbVie position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in AbbVie will appreciate offsetting losses from the drop in the long position's value.Moving together with AbbVie Stock
| 0.85 | EOLS | Evolus Inc Financial Report 14th of May 2024 | PairCorr |
Moving against AbbVie Stock
| 0.42 | LPTX | Leap Therapeutics Financial Report 20th of May 2024 | PairCorr |
The ability to find closely correlated positions to AbbVie could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace AbbVie when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back AbbVie - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling AbbVie Inc to buy it.
The correlation of AbbVie is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as AbbVie moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if AbbVie Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for AbbVie can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AbbVie Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the AbbVie Inc information on this page should be used as a complementary analysis to other AbbVie's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Complementary Tools for AbbVie Stock analysis
When running AbbVie's price analysis, check to measure AbbVie's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AbbVie is operating at the current time. Most of AbbVie's value examination focuses on studying past and present price action to predict the probability of AbbVie's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AbbVie's price. Additionally, you may evaluate how the addition of AbbVie to your portfolios can decrease your overall portfolio volatility.
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |
Is AbbVie's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AbbVie. If investors know AbbVie will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AbbVie listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.67) | Dividend Share 5.99 | Earnings Share 2.72 | Revenue Per Share 30.723 | Quarterly Revenue Growth (0.05) |
The market value of AbbVie Inc is measured differently than its book value, which is the value of AbbVie that is recorded on the company's balance sheet. Investors also form their own opinion of AbbVie's value that differs from its market value or its book value, called intrinsic value, which is AbbVie's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AbbVie's market value can be influenced by many factors that don't directly affect AbbVie's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AbbVie's value and its price as these two are different measures arrived at by different means. Investors typically determine if AbbVie is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AbbVie's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.